Skip to main content

Table 3 Incidence of multiplicity colonic mucosal ulcer and dysplasia.

From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands

Group no. Treatment Incidence (%) Multiplicity (no. of lesions / mouse, means ± SD)
   Mucosal ulcer Total dysplasia Dysplasia with: Mucosal ulcer Total dysplasia Dysplasia with:
     Mild atypia Severe atypia    Mild atypia Severe atypia
1 AOM/DSS 40% 90% 80% 50% 0.5 ± 0.7 3.2 ± 1.5 1.4 ± 1.0 1.1 ± 1.3
2 AOM/DSS/0.04% Nimesulide 10% 90% 80% 50% 0.1 ± 0.3 2.2 ± 2.3 1.2 ± 0.9 0.6 ± 0.7
3 AOM/DSS/0.05% Troglitazone 20% 90% 50% 30% 0.3 ± 0.7 2.1 ± 2.2 0.7 ± 0.8 0.8 ± 1.6
4 AOM/DSS/0.05% Bezafibrate 30% 80% 60% 20% 0.4 ± 0.7 1.9 ± 1.8 0.9 ± 1.0 0.4 ± 0.8
\